Characteristics and outcomes of 12 patients who received blinatumomab and/or inotuzumab ozogamicin as a salvage therapy for post–CAR T disease progression
| . | . | . | . | Blinatumomab . | Inotuzumab . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Drugs . | Prior immuno-therapy exposure before CAR T-cell therapy . | CD19 status at relapse after CAR T-cell therapy . | Time from CAR T-cells to blinatumomab (d) . | CRS (grade) . | Neuro-toxicities (grade) . | Cytopenia grade 3 or higher . | Response to blinatumomab . | Time from CAR T- cells to inotuzumab (d) . | Cytopenia grade 3 or higher . | SOS . | Response to inotuzumab . | Survival status at last contact . | Cause of death . |
| MSK15 | Blinatumomab | No | Positive | 1500 | Yes (grade 2) | Yes (grade 1) | No | MRD− CR | — | — | — | — | Alive | — |
| MSK34 | Blinatumomab | No | Positive | 318 | Yes (unknown) | Yes (unknown) | Unknown | MRD− CR | — | — | — | — | Dead | Disease |
| MSK39 | Blinatumomab | No | Positive | 54 | Yes (unknown) | Yes (unknown) | Unknown | CR | — | — | — | — | Alive | — |
| MSK56 | Blinatumomab | No | Positive | 361 | No | No | No | NR | — | — | — | — | Dead | Unknown |
| MSK26 | Inotuzumab | No | Negative | — | — | — | — | — | 253 | Grade 4 WBC; grade 4 platelet | Yes | Unknown | Dead | TRM |
| MSK44 | Inotuzumab | Blinatumomab | Negative | — | — | — | — | — | 564 | Grade 4 WBC; grade 4 platelet | No | MRDȒ CR | Alive | — |
| MSK46 | Inotuzumab | No | — | — | — | — | — | — | 484 | Grade 4 WBC | No | Unknown | Dead | Disease |
| MSK50 | Inotuzumab | Blinatumomab | Negative | — | — | — | — | — | 136 | Grade 4 WBC; grade 4 platelet | Yes (after alloHSCT) | MRD+ CR | Dead | Disease |
| MSK53 | Inotuzumab | Blinatumomab | Positive | — | — | — | — | — | 198 | Grade 4 WBC; grade 4 platelet | No | CR | Dead | Disease |
| MSK29 | Blinatumomab then inotuzumab | No | Positive | 895 | Yes (grade 1) | No | No | NR | 965 | Grade 3 WBC; grade 4 platelet | No | NR | Dead | Disease |
| MSK35 | Blinatumomab then inotuzumab | No | Positive | 73 | No | No | Unknown | NR | 116 | Grade 4 WBC; grade 4 platelet | No | MRD+ CR | Dead | TRM |
| MSK55 | Blinatumomab then inotuzumab | No | Positive | 90 | Yes (grade 1) | No | No | NR | 229 | Grade 4 WBC; grade 4 platelet | No | NR | Dead | Disease |
| . | . | . | . | Blinatumomab . | Inotuzumab . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Drugs . | Prior immuno-therapy exposure before CAR T-cell therapy . | CD19 status at relapse after CAR T-cell therapy . | Time from CAR T-cells to blinatumomab (d) . | CRS (grade) . | Neuro-toxicities (grade) . | Cytopenia grade 3 or higher . | Response to blinatumomab . | Time from CAR T- cells to inotuzumab (d) . | Cytopenia grade 3 or higher . | SOS . | Response to inotuzumab . | Survival status at last contact . | Cause of death . |
| MSK15 | Blinatumomab | No | Positive | 1500 | Yes (grade 2) | Yes (grade 1) | No | MRD− CR | — | — | — | — | Alive | — |
| MSK34 | Blinatumomab | No | Positive | 318 | Yes (unknown) | Yes (unknown) | Unknown | MRD− CR | — | — | — | — | Dead | Disease |
| MSK39 | Blinatumomab | No | Positive | 54 | Yes (unknown) | Yes (unknown) | Unknown | CR | — | — | — | — | Alive | — |
| MSK56 | Blinatumomab | No | Positive | 361 | No | No | No | NR | — | — | — | — | Dead | Unknown |
| MSK26 | Inotuzumab | No | Negative | — | — | — | — | — | 253 | Grade 4 WBC; grade 4 platelet | Yes | Unknown | Dead | TRM |
| MSK44 | Inotuzumab | Blinatumomab | Negative | — | — | — | — | — | 564 | Grade 4 WBC; grade 4 platelet | No | MRDȒ CR | Alive | — |
| MSK46 | Inotuzumab | No | — | — | — | — | — | — | 484 | Grade 4 WBC | No | Unknown | Dead | Disease |
| MSK50 | Inotuzumab | Blinatumomab | Negative | — | — | — | — | — | 136 | Grade 4 WBC; grade 4 platelet | Yes (after alloHSCT) | MRD+ CR | Dead | Disease |
| MSK53 | Inotuzumab | Blinatumomab | Positive | — | — | — | — | — | 198 | Grade 4 WBC; grade 4 platelet | No | CR | Dead | Disease |
| MSK29 | Blinatumomab then inotuzumab | No | Positive | 895 | Yes (grade 1) | No | No | NR | 965 | Grade 3 WBC; grade 4 platelet | No | NR | Dead | Disease |
| MSK35 | Blinatumomab then inotuzumab | No | Positive | 73 | No | No | Unknown | NR | 116 | Grade 4 WBC; grade 4 platelet | No | MRD+ CR | Dead | TRM |
| MSK55 | Blinatumomab then inotuzumab | No | Positive | 90 | Yes (grade 1) | No | No | NR | 229 | Grade 4 WBC; grade 4 platelet | No | NR | Dead | Disease |
NR, no response; TRM, treatment-related mortality; WBC, white blood cell.